No Data
No Data
Linuo Pharmaceutical (301188): Production capacity is gradually being put into operation, expecting the speed of molded bottle output to accelerate.
Event 1: The company released the 2024 annual report, achieving an annual revenue of 1.08 billion, with a year-on-year increase of +14.1%; net profit attributable to parent company of 0.066 billion, with a year-on-year increase of +0.2%; and net profit attributable to parent company after deducting non-recurring gains and losses of 0.056 billion, with a year-on-year increase of +4.4%. 24
Linuo Drug Package (301188): Q1 performance shows significant growth, and the release of borosilicate products is expected.
Q1 performance shows significant growth, the release of medium borosilicate products is expected, maintaining a "Buy" rating. The company released its 2024 annual report and 2025 Q1 report, achieving revenue of 1.081 billion yuan in 2024, +14.09% year-on-year.
Lihua Pharmaceutical (301188): Q1 revenue shows steady growth and gross margin has significantly improved.
Event description: In 2024, revenue reached 1.081 billion, a year-on-year increase of 14.09%; net income attributable was 0.066 billion, a year-on-year increase of 0.23%; Q4 revenue was 0.25 billion, a year-on-year decrease of 2.39%;.
Linuo Pharmaceuticals: 2024 Annual Report Summary
Linuo Pharmacopoeia: 2024 Annual Report
Linuo Pharmacopoeia: Report for the first quarter of 2025